1353 related articles for article (PubMed ID: 25301759)
1. Nomogram Predicting Prostate Cancer-specific Mortality for Men with Biochemical Recurrence After Radical Prostatectomy.
Brockman JA; Alanee S; Vickers AJ; Scardino PT; Wood DP; Kibel AS; Lin DW; Bianco FJ; Rabah DM; Klein EA; Ciezki JP; Gao T; Kattan MW; Stephenson AJ
Eur Urol; 2015 Jun; 67(6):1160-1167. PubMed ID: 25301759
[TBL] [Abstract][Full Text] [Related]
2. Are biochemical recurrence outcomes similar after radical prostatectomy and radiation therapy? Analysis of prostate cancer-specific mortality by nomogram-predicted risks of biochemical recurrence.
Lee BH; Kibel AS; Ciezki JP; Klein EA; Reddy CA; Yu C; Kattan MW; Stephenson AJ
Eur Urol; 2015 Feb; 67(2):204-9. PubMed ID: 25294696
[TBL] [Abstract][Full Text] [Related]
3. Do nomograms designed to predict biochemical recurrence (BCR) do a better job of predicting more clinically relevant prostate cancer outcomes than BCR? A report from the SEARCH database group.
Teeter AE; Presti JC; Aronson WJ; Terris MK; Kane CJ; Amling CL; Freedland SJ
Urology; 2013 Jul; 82(1):53-8. PubMed ID: 23806388
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Implications of Multiparametric Magnetic Resonance Imaging and Concomitant Systematic Biopsy in Predicting Biochemical Recurrence After Radical Prostatectomy in Prostate Cancer Patients Diagnosed with Magnetic Resonance Imaging-targeted Biopsy.
Gandaglia G; Ploussard G; Valerio M; Marra G; Moschini M; Martini A; Roumiguié M; Fossati N; Stabile A; Beauval JB; Malavaud B; Scuderi S; Barletta F; Afferi L; Rakauskas A; Gontero P; Mattei A; Montorsi F; Briganti A
Eur Urol Oncol; 2020 Dec; 3(6):739-747. PubMed ID: 32847747
[TBL] [Abstract][Full Text] [Related]
5. The CPC Risk Calculator: A New App to Predict Prostate-specific Antigen Recurrence During Follow-up After Radical Prostatectomy.
Røder MA; Berg KD; Loft MD; Thomsen FB; Ferrari M; Kurbegovic S; Rytgaard HC; Gruschy L; Brasso K; Gerds TA; Kjær A; Brooks JD; Iversen P
Eur Urol Focus; 2018 Apr; 4(3):360-368. PubMed ID: 28753827
[TBL] [Abstract][Full Text] [Related]
6. Prediction of outcome following early salvage radiotherapy among patients with biochemical recurrence after radical prostatectomy.
Briganti A; Karnes RJ; Joniau S; Boorjian SA; Cozzarini C; Gandaglia G; Hinkelbein W; Haustermans K; Tombal B; Shariat S; Sun M; Karakiewicz PI; Montorsi F; Van Poppel H; Wiegel T
Eur Urol; 2014 Sep; 66(3):479-86. PubMed ID: 24345725
[TBL] [Abstract][Full Text] [Related]
7. Postoperative prostate-specific antigen nadir improves accuracy for predicting biochemical recurrence after radical prostatectomy: Results from the Shared Equal Access Regional Cancer Hospital (SEARCH) and Duke Prostate Center databases.
Moreira DM; Presti JC; Aronson WJ; Terris MK; Kane CJ; Amling CL; Sun LL; Moul JW; Freedland SJ
Int J Urol; 2010 Nov; 17(11):914-22. PubMed ID: 20880361
[TBL] [Abstract][Full Text] [Related]
8. Optimal definition of biochemical recurrence after radical prostatectomy depends on pathologic risk factors: identifying candidates for early salvage therapy.
Mir MC; Li J; Klink JC; Kattan MW; Klein EA; Stephenson AJ
Eur Urol; 2014 Aug; 66(2):204-10. PubMed ID: 24007712
[TBL] [Abstract][Full Text] [Related]
9. Markers and meaning of primary treatment failure.
Swindle PW; Kattan MW; Scardino PT
Urol Clin North Am; 2003 May; 30(2):377-401. PubMed ID: 12735513
[TBL] [Abstract][Full Text] [Related]
10. Integrating Prostate-specific Antigen Kinetics into Contemporary Predictive Nomograms of Salvage Radiotherapy After Radical Prostatectomy.
Campbell SR; Tom MC; Agrawal S; Efstathiou JA; Michalski JM; Abramowitz MC; Pollack A; Spratt DE; Hearn JWD; Stephans KL; Gao T; Li J; Tendulkar RD
Eur Urol Oncol; 2022 Jun; 5(3):304-313. PubMed ID: 34016556
[TBL] [Abstract][Full Text] [Related]
11. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H
Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
[TBL] [Abstract][Full Text] [Related]
12. Long-term cancer control outcomes in patients with biochemical recurrence and the impact of time from radical prostatectomy to biochemical recurrence.
Pompe RS; Gild P; Karakiewicz PI; Bock LP; Schlomm T; Steuber T; Graefen M; Huland H; Tian Z; Tilki D
Prostate; 2018 Jun; 78(9):676-681. PubMed ID: 29570821
[TBL] [Abstract][Full Text] [Related]
13. Predicting pathological outcomes in patients undergoing robot-assisted radical prostatectomy for high-risk prostate cancer: a preoperative nomogram.
Abdollah F; Klett DE; Sood A; Sammon JD; Pucheril D; Dalela D; Diaz M; Peabody JO; Trinh QD; Menon M
BJU Int; 2015 Nov; 116(5):703-12. PubMed ID: 25413443
[TBL] [Abstract][Full Text] [Related]
14. Biochemical recurrence-free conditional probability after radical prostatectomy: A dynamic prognosis.
García-Barreras S; Sanchez-Salas R; Mejia-Monasterio C; Muttin F; Secin F; Dell'Oglio P; Nunes-Silva I; Srougi V; Barret E; Rozet F; Prapotnich D; Cathelineau X
Int J Urol; 2019 Jul; 26(7):725-730. PubMed ID: 31001870
[TBL] [Abstract][Full Text] [Related]
15. Predicting survival of men with recurrent prostate cancer after radical prostatectomy.
Dell'Oglio P; Suardi N; Boorjian SA; Fossati N; Gandaglia G; Tian Z; Moschini M; Capitanio U; Karakiewicz PI; Montorsi F; Karnes RJ; Briganti A
Eur J Cancer; 2016 Feb; 54():27-34. PubMed ID: 26707594
[TBL] [Abstract][Full Text] [Related]
16. Identifying the best candidate for radical prostatectomy among patients with high-risk prostate cancer.
Briganti A; Joniau S; Gontero P; Abdollah F; Passoni NM; Tombal B; Marchioro G; Kneitz B; Walz J; Frohneberg D; Bangma CH; Graefen M; Tizzani A; Frea B; Karnes RJ; Montorsi F; Van Poppel H; Spahn M
Eur Urol; 2012 Mar; 61(3):584-92. PubMed ID: 22153925
[TBL] [Abstract][Full Text] [Related]
17. Long-term cancer control outcomes in patients with clinically high-risk prostate cancer treated with robot-assisted radical prostatectomy: results from a multi-institutional study of 1100 patients.
Abdollah F; Sood A; Sammon JD; Hsu L; Beyer B; Moschini M; Gandaglia G; Rogers CG; Haese A; Montorsi F; Graefen M; Briganti A; Menon M
Eur Urol; 2015 Sep; 68(3):497-505. PubMed ID: 26119559
[TBL] [Abstract][Full Text] [Related]
18. Impact of international variation of prostate cancer on a predictive nomogram for biochemical recurrence in clinically localised prostate cancer.
Cho YM; Jung SJ; Cho N; Kim MJ; Kattan MW; Yu C; Ahn H; Ro JY;
World J Urol; 2014 Apr; 32(2):399-405. PubMed ID: 23765315
[TBL] [Abstract][Full Text] [Related]
19. Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era.
Stephenson AJ; Kattan MW; Eastham JA; Bianco FJ; Yossepowitch O; Vickers AJ; Klein EA; Wood DP; Scardino PT
J Clin Oncol; 2009 Sep; 27(26):4300-5. PubMed ID: 19636023
[TBL] [Abstract][Full Text] [Related]
20. Outcomes of men with an elevated prostate-specific antigen (PSA) level as their sole preoperative intermediate- or high-risk feature.
Faisal FA; Sundi D; Pierorazio PM; Ball MW; Humphreys EB; Han M; Epstein JI; Partin AW; Carter HB; Bivalacqua TJ; Schaeffer EM; Ross AE
BJU Int; 2014 Dec; 114(6b):E120-E129. PubMed ID: 24731026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]